Top Markets
Coin of the day
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
Clasificación en acciones #6395
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Precio por acción
$33.00
Capitalización bursátil
$2.08B
Cambio (1 día)
-0.12%
Cambio (1 año)
97.49%
País
US
Comercio Zenas BioPharma, Inc. (ZBIO)

Categoría

EPS de Zenas BioPharma, Inc. (ZBIO)
EPS a fecha de 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Zenas BioPharma, Inc., el EPS actual de la empresa (TTM) es 0. Al final del año 2026, la empresa tenía un EPS de 0 igual a al EPS de 2026, que fue de 0.
Historial de EPS de Zenas BioPharma, Inc. desde 2026 hasta 2026
EPS al final de cada año
Año EPS Cambiar
Not enough data for the provided dates.
EPS de empresas similares o competidoras
Empresa EPS Diferencia de EPS País
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH